Inhibition of TLR4/IL-1R in BALB/c mouse BMDM assessed as downregulation of LPS-stimulated MyD88 expression at 5 ug/mL preincubated for 2 hrs followed by LPS challenge measured after 18 hrs by flow cytometric analysis (Rvb = 127%)
Inhibition of TLR4/IL-1R in BALB/c mouse BMDM assessed as downregulation of LPS-stimulated MyD88 protein expression at 5 ug/mL after 20 hrs by Western blotting analysis relative to control
Inhibition of TLR4/IL-1R in BALB/c mouse BMDM assessed as downregulation of LPS-stimulated MyD88 protein expression at 1 ug/mL after 20 hrs by Western blotting analysis relative to control
Inhibition of TLR4 in ovalbumin pulsed C57BL/6 mouse BMDC co-cultured with OT-2 CD4+ T cells assessed as reduction of LPS-induced IL-17 production at 5 ug/mL after 3 days by ELISA
Inhibition of TLR4 in ovalbumin pulsed BALB/c mouse BMDC co-cultured with DO-11.10 CD4+ T cells assessed as reduction of LPS-induced IL-17 production at 5 ug/mL after 3 days by ELISA
Inhibition of TLR4 in C57BL/6 mouse BMDC assessed as reduction of LPS-induced IL-23 production at 5 ug/mL preincubated for 2 hrs prior to LPS challenge measured after 24 hrs by ELISA
Inhibition of TLR4 in C57BL/6 mouse BMDC assessed as reduction of LPS-induced IL-6 production at 5 ug/mL preincubated for 2 hrs prior to LPS challenge measured after 24 hrs by ELISA
Inhibition of TLR4 in C57BL/6 mouse BMDC assessed as reduction of LPS-induced TNF-alpha production at 5 ug/mL preincubated for 2 hrs prior to LPS challenge measured after 24 hrs by ELISA
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in serum level of IL-17 at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by ELISA
Antiinflammatory activity in DBA/1 mouse assessed as reduction in number of PMA/ionomycin-stimulated gammadelta+ T cells expressing IL-17 at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by flow cytometric analysis relative to control
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in number of PMA/ionomycin-stimulated CD4+ T cells expressing IL-17 at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by flow cytometric analysis relative to control
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in number of PMA/ionomycin-stimulated total DLN cells expressing IL-17 at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by flow cytometric analysis relative to control
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as effect on number of PMA/ionomycin-stimulated gammadelta+ T cells expressing IFNgamma at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by flow cytometric analysis relative to control
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in number of PMA/ionomycin-stimulated CD4+ T cells expressing IFNgamma at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by flow cytometric analysis relative to control
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in number of PMA/ionomycin-stimulated CD8+ T cells expressing IFNgamma at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by flow cytometric analysis relative to control
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in number of PMA/ionomycin-stimulated total DLN cells expressing IFNgamma at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge by flow cytometric analysis relative to control
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in number of gammadelta+ T cells at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge
Antiinflammatory activity in DBA/1 mouse collagen-induced arthritis model assessed as reduction in number of CD8+ T cells at 50 ug/kg, sc administered 2 days prior to collagen challenge continued till day 21 post collagen challenge